Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)

What happened: Intellia Therapeutics (Nasdaq: NTLA) said it completed enrollment in MAGNITUDE-2, its Phase 3 trial of nex-z in patients with ATTRv-PN. Key numbers: About 60 patients randomized 1:1 to a single 55 mg infusion of nex-z or placebo. Why it matters: CEO John Leonard called completion a pivotal step toward a potentially transformative one-time treatment. Investigator John L. Berk said a single-dose agent that substantially reduces TTR would be a meaningful advancement for patients who continue to progress. Market: +1.7% today ($11.86), +28.8% YTD, 0.7x vol — as of 12:15 UTC

Intellia Therapeutics (Nasdaq: NTLA) said it completed enrollment in MAGNITUDE-2, its Phase 3 trial of nex-z in patients with ATTRv-PN.

CEO John Leonard called completion a pivotal step toward a potentially transformative one-time treatment. Investigator John L. Berk said a single-dose agent that substantially reduces TTR would be a meaningful advancement for patients who continue to progress. Market: +1.7% today ($11.86), +28.8% YTD, 0.7x vol — as of 12:15 UTC